Business Model & Revenue
Silence Therapeutics is a clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies using its proprietary mRNAi GOLD platform. Unlike mRNA vaccines which produce proteins, siRNA silences specific disease-causing genes by destroying the messenger RNA that carries their instructions. Silence's platform targets genes expressed in the liver, leveraging the organ's natural uptake of siRNA conjugates.
The company monetizes through a hybrid model: proprietary assets developed in-house (divesiran for PV and other blood disorders) and partnered programs developed with larger pharma companies. The most significant partnership is with AstraZeneca for SLN312/AZD1705, an ANGPTL3-targeting siRNA for dyslipidemia that showed promising Phase 1 data at the EAS 2026 Congress. AstraZeneca funds development and pays milestones and royalties. The deferred revenue of $55.2M on the balance sheet reflects upfront collaboration payments being recognized over the development period.
Divesiran is Silence's wholly owned lead asset, meaning the company retains full economics on the PV program. If approved, divesiran would commercialize through a focused rare disease infrastructure or via a partnership. The company also has two preclinical programs — SLN365 (GPR146 for dyslipidemia) and SLN098 (INHBE for obesity/metabolic disease) — both positioned for potential IND filings in 2027.
Financial Highlights
Income Statement (in thousands, except per share)
| Metric | Q2 2026 | Q2 2025 | H1 2026 | H1 2025 |
|---|---|---|---|---|
| Revenue | $0 | $224 | $422 | $366 |
| R&D Expenses | ($9,148) | ($17,647) | ($18,270) | ($38,460) |
| G&A Expenses | ($4,717) | ($5,131) | ($11,743) | ($12,815) |
| Operating Loss | ($13,865) | ($23,963) | ($29,602) | ($52,372) |
| Net Loss | ($12,268) | ($27,354) | ($27,225) | ($55,884) |
| EPS (basic) | ($0.09) | ($0.19) | ($0.19) | ($0.39) |
Balance Sheet (June 30, 2026)
| Item | Amount |
|---|---|
| Cash & Equivalents | $72.1M |
| R&D Benefit Receivable | $9.3M |
| Total Current Assets | $94.3M |
| Total Assets | $106.4M |
| Total Liabilities | $67.9M |
| Contract Liabilities (deferred rev) | $55.2M |
| Ordinary Shares Outstanding | 141.7M |
Cash Runway: Net cash consumption was approximately $13M in H1 2026. At this rate, the company has runway into late 2028. Phase 3 initiation for divesiran in 1H 2027 will increase burn, but $55.2M in deferred collaboration revenue continues converting to offset R&D spend.
Competitive Landscape
Silence operates in the siRNA therapeutics space and the PV treatment market. In siRNA, the field is anchored by Alnylam, which has established the commercial viability of the modality with approved drugs like Onpattro and Amvuttra. Silence's mRNAi GOLD platform differentiates through its conjugation chemistry and liver-targeting approach.
PV Treatment Competitors:
- PharmaEssor (BESREMi): Approved interferon ropeginterferon alfa-2b for PV. Requires frequent injections and carries interferon-related side effects. Does not specifically target iron metabolism or red blood cell production.
- Incyte (Jakafi): Approved ruxolitinib for PV patients with splenomegaly who are intolerant or resistant to hydroxyurea. JAK inhibitor mechanism with boxed warning risks. Annual revenue exceeds $1B across indications.
- Hydroxyurea (generic): Standard cytoreductive therapy for PV. Cheap, widely used, but carries DNA synthesis inhibition risks and variable efficacy.
- Phlebotomy: The foundational treatment for PV — physically removing blood to reduce hematocrit. Burdensome, does not address underlying red blood cell overproduction.
- Alnylam (ALN-TMPSS6): Also developing TMPRSS6-targeting siRNA for beta-thalassemia and potentially PV, creating a direct platform competitor, though Silence has a clinical lead in PV specifically.
Moats:
- First-in-class clinical validation of TMPRSS6 silencing in PV with Phase 2 data
- FDA Fast Track and Orphan Drug designations providing regulatory advantages
- Proprietary mRNAi GOLD platform with differentiated conjugation chemistry
- AstraZeneca partnership validating platform approach for cardiovascular indications
- Quarterly dosing regimen (Q12W) supporting patient compliance if approved
Catalysts
-
Phase 3 SANRECO trial initiation (1H 2027): The pivotal trial evaluating divesiran Q12W vs. placebo in PV patients will be the primary value driver. Positive Phase 3 data would support an accelerated approval pathway given Fast Track and Orphan Drug status.
-
Full Phase 2 SANRECO data presentation (H2 2026): Management plans to present complete results including secondary endpoints and patient-reported outcomes at an upcoming medical congress, which could further validate the best-in-class profile.
-
AstraZeneca SLN312/AZD1705 advancement: Phase 1 data showed durable LDL-C and ANGPTL3 reductions. AZ's decision on Phase 2 advancement could trigger milestones and validate the platform beyond PV.
-
Preclinical pipeline IND filings (2027): SLN365 (GPR146) and SLN098 (INHBE) are both positioned for potential IND filings in 2027, expanding the pipeline into dyslipidemia and obesity.
-
Business development for divesiran ex-US rights: Silence retains full global economics on divesiran and could partner ex-US rights to fund Phase 3 development without dilutive financing.
Key Risks
- Clinical trial risk — Phase 3 trials for divesiran may fail to replicate the Phase 2 efficacy or may reveal safety issues not seen in the smaller Phase 2 population, which would dramatically devalue the stock
- Funding and dilution risk — Phase 3 PV trial costs will increase cash burn beyond current runway; the company may need to raise capital through equity offering, partnership, or dilutive financing before data readout
- Competition from established PV therapies — Besremi and Jakafi are FDA-approved with established prescriber networks; divesiran would need to demonstrate clear superiority to gain formulary access
- Regulatory risk — The FDA may require additional studies or impose restrictions on the Phase 3 design, delaying the development timeline beyond the planned 1H 2027 initiation
- Platform and partnership dependence — AstraZeneca can discontinue the SLN312 collaboration; loss of partnered revenue and validation would negatively impact the platform valuation thesis
Our Thesis
The market is pricing SLN as a single-asset PV play, but the mRNAi GOLD platform is the real story. Divesiran's 88% response rate and clean safety position it as a potential best-in-class therapy in PV, where current treatment relies on generic cytoreductives and repeated phlebotomies. No approved therapy targets iron metabolism to control red blood cell production. The Q12W dosing arm's 81.3% response supports a convenient quarterly regimen. Beyond divesiran, Silence has an AstraZeneca-partnered ANGPTL3 program that showed Phase 1 lipid reductions at EAS 2026, plus two preclinical programs targeting IND filings in 2027.
Our $20.00 PT uses a risk-adjusted NPV. The PV addressable market is approximately 100,000 patients in the US and EU; at $50,000 annual pricing, TAM exceeds $5B. Applying 15% approval probability (standard for Phase 2 assets entering Phase 3) and a 4x peak sales multiple on $500M risk-adjusted revenue yields a divesiran valuation near $750M. Adding platform value from the AZ-partnered ANGPTL3 program and the two preclinical assets, plus $72.1M cash and $55.2M in deferred collaboration revenue, gives a total enterprise value near $800M, or roughly $20 per ADS equivalent at current share count.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.